| Category | Brightening Skincare |
| Founded | 2016 |
| Headquarters | Guangzhou |
| Listing | Private; parent reported to be in IPO process (C2CC, Apr 2026) |
| Latest revenue | No audited financials disclosed |
| Hero SKUs | Glabridin Brightening Serum |
Brand History
Founded in Guangzhou in 2016 and named after a solar term, Guyu built its identity on oriental botanicals plus modern research. The breakthrough was ingredient choice: with brightening dominated by niacinamide and vitamin C, Guyu picked glabridin — costlier, gentler — and built content around 'brightening without building tolerance', sidestepping a head-on fight with international brands.
From 2021 it scaled on Douyin and Xiaohongshu through ingredient explainers and cultural storytelling, with the glabridin serum becoming a hit at RMB 200-300, while 'valley' concept stores reinforced the oriental feel offline. C2CC reported in April 2026 that its parent has entered the IPO process with revenue in the RMB 2-5bn range; as a private company, year-by-year figures are not publicly verifiable.
Hero Products
Three-Year Financials
Neither the brand nor its parent publishes audited annual financials; no estimates are provided.
Brand-level：C2CC reports parent revenue in the RMB 2-5bn range without year-by-year figures; the prospectus data has not been verified for this site.
Source：C2CC Media (Apr 2026); brand information
Company Coverage
- 2026-04Parent enters IPO process
C2CC reports that the companies behind Chando, HBN, Guyu and Half Acre are all pursuing listings, with revenue in the RMB 2-5bn range.
Source：C2CC Media - 2025-09Chinese skin research released
Tolerance data for glabridin on Asian skin, produced with universities.
Source：Brand - 2025-05More licensed brightening products
Multiple SKUs obtained China's special cosmetics licence.
Source：Brand
Observation: Guyu turning glabridin into brand equity is a rare successful case of single-ingredient positioning. The advantage is a clear memory hook; the risk is that once the ingredient is widely copied or a stronger alternative appears, the moat thins quickly. The brightening licence and tolerance data are therefore not just compliance but the key barrier sustaining its premium.